We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Antidepressiva | SpringerLink

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content
SpringerLink
Log in

Antidepressiva

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • 1777 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden einmal im allgemeinen Teil und dann für jedes Antidepressivum spezifisch im Präparateteil beschrieben. Jedes Präparat wird bewertet. In einem eigenen Abschnitt werden die Unterschiede der Antidepressiva in Bezug auf Wirksamkeit und Nebenwirkungen analysiert. Alle Indikationen für Antidepressiva, von den depressiven Störungen über die Angst- und Zwangsstörungen bis zu den Trauma- und belastungsbezogenen Störungen, werden abgehandelt. Der Schwerpunkt liegt auch in dieser Auflage im praktischen Umgang mit Antidepressiva.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Abdallah CG, Roache JD, Gueorguieva R, Krystal JH (2022) Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 47(8):1574–1581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • AFFINITY Trial Collaboration (2020) Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 19(8):651–660

    Article  Google Scholar 

  • Almeida OP, Hankey GJ, Ford A et al (2021) Assessment of Fluoxetine in Stroke Recovery (AFFINITY) Trial Collaboration. Depression outcomes among patients related with fluoxetine for stroke recovery: The AFFINITY Randomized Clinical Trial. JAMA Neurol 78(9):1072–1079

    Article  PubMed  Google Scholar 

  • Arad G, Azriel O, Pine DS et al (2023) Attention bias modification treatment versus a selective serotonin reuptake inhibitor or waiting list control for social anxiety disorder: a randomized clinical trial. Am J Psychiatry 180(5):357–366

    Article  PubMed  Google Scholar 

  • Bahji A, Vazquez GH, Zarate CA Jr (2021) Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 278:542–555

    Article  CAS  PubMed  Google Scholar 

  • Bahji A, Zarate CA, Vazquez GH (2022) Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf 21(6):853–866

    Article  PubMed  PubMed Central  Google Scholar 

  • Bandelow B, Sagebiel A, Belz M et al (2018) Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry 212(6):333–338

    Article  PubMed  Google Scholar 

  • Bandelow B, Aden I, Alpers GW et al (2021) Deutsche S3-Leitlinie Behandlung von Angststörungen, Version 2. https://register.awmf.org/de/leitlinien/detail/051-028. Zugegriffen: 25. Mai 2023

  • Bartels C, Wagner M, Wolfsgruber S et al (2018) Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry 175(3):232–241

    Article  PubMed  Google Scholar 

  • Batelaan NM, Bosman RC, Muntingh A et al (2017) Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ 358:j3927

    Article  PubMed  PubMed Central  Google Scholar 

  • Berlit P et al (2023) Neurologische Manifestationen bei COVID-19, S2k-Leitlinie, 2022. In: Deutsche Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie

    Google Scholar 

  • Blumenthal JA, Smith PJ, Jiang W et al (2021) Effect of exercise, escitalopram, or placebo on anxiety in patients with coronary heart disease: the understanding the benefits of exercise and escitalopram in anxious patients with coronary heart disease (UNWIND) randomized clinical trial. Jama Psychiatry 78(11):1270–1278

    Article  PubMed  Google Scholar 

  • Bockting CLH, Klein NS, Elgersma HJ et al (2018) Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. Lancet Psychiatry 5(5):401–410

    Article  PubMed  Google Scholar 

  • Bonaventura J, Lam S, Carlton M et al (2021) Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry 26(11):6704–6722

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Braun C, Adams A, Rink L et al (2020) In search of a dose-response relationship in SSRIs – a systematic review, meta-analysis, and network meta-analysis. Acta Psychiatr Scand 142(6):430–442

    Article  CAS  PubMed  Google Scholar 

  • Brännström J, Lövheim H, Gustafson Y et al (2019) Association between antidepressant drug use and hip fracture in older people before and after treatment initiation. JAMA Psychiatry 76(2):172–179

    Article  PubMed  PubMed Central  Google Scholar 

  • Breedvelt JJF, Warren FC, Segal Z et al (2021) Continuation of antidepressants vs sequential psychological interventions to prevent relapse in depression: an individual participant data meta-analysis. JAMA Psychiatry 78(8):868–875

    Article  PubMed  Google Scholar 

  • Brouwer A, Nguyen HT, Snoek FJ et al (2017) Light therapy: is it safe for the eyes? Acta Psychiatr Scand 136(6):534–548

    Article  CAS  PubMed  Google Scholar 

  • Brunet A, Saumier D, Liu A et al (2018) Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial. Am J Psychiatry 175(5):427–433

    Article  PubMed  Google Scholar 

  • Bykov K, Schneeweiss S, Donneyong MM et al (2017) Impact of an interaction between clopidogrel and selective serotonin reuptake inhibitors. Am J Cardiol 119(4):651–657

    Article  CAS  PubMed  Google Scholar 

  • Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2022) Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, Version 3.1. 2022. www.leitlinien.de/depression. Zugegriffen: 4. März 2023

  • Castello JP, Pasi M, Kubiszewski P et al (2022) Cerebral small vessel disease and depression among intracerebral hemorrhage survivors. Stroke 53(2):523–531

    Article  PubMed  Google Scholar 

  • Caye A, Pilz LK, Maia AL et al (2020) The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol 33:139–145

    Article  CAS  PubMed  Google Scholar 

  • Cipriani A, Furukawa TA, Salanti G et al (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Correia-Melo FS, Leal GC, Vieira F et al (2020) Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord 264:527–534

    Article  CAS  PubMed  Google Scholar 

  • COVID-19 Mental Disorders Collaborators (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398(10312):1700–1712

    Article  Google Scholar 

  • Cuijpers P, Quero S, Noma H et al (2021) Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry 20(2):283–293

    Article  PubMed  PubMed Central  Google Scholar 

  • Davis AK, Barrett FS, May DG et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481–489

    Article  PubMed  Google Scholar 

  • Deligiannidis KM, Meltzer-Brody S et al (2021) Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 78(9):951–959

    Article  PubMed  Google Scholar 

  • DeRubeis RJ, Zajecka J, Shelton RC et al (2019) Depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: a phase 2 randomized clinical trial. JAMA Psychiatry 77(3):237–245

    Article  PubMed Central  Google Scholar 

  • DGPPN (Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V.) (2022) Stellungnahme der DGPPN zur den „Indikationen der EKT“. Nervenheilkunde 41:706–709

    Google Scholar 

  • Dietrichs ES, Smith GL (2022) Prediction of ventricular arrhythmias by QRS/QTc-ratio in citalopram or escitalopram intoxication. Front Med 9:866454

    Article  Google Scholar 

  • Difede J, Rothbaum BO, Rizzo AA et al (2022) Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer. Transl Psychiatry 12(1):299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dold M, Bartova L, Kasper S (2020) Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment. Int J Neuropsychopharmacol 23(7):440–445

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Douros A, Dell’Aniello S, Dehghan G et al (2019) Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: a cohort study. Neurology 93(10):e1010–e1020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dragioti E, Solmi M, Favaro A et al (2019) Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 76(12):1241–1255

    Article  PubMed  PubMed Central  Google Scholar 

  • Dudas R, Malouf R, McCleery J, Dening T (2018) Antidepressants for treating depression in dementia. Cochrane Database Syst Rev 8(8):CD 3944

    Google Scholar 

  • Dunlop BW, LoParo D, Kinkead B et al (2019) Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry 176(4):275–286

    Article  PubMed  PubMed Central  Google Scholar 

  • EFFECTS Trial Collaboration (2020) Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 19(8):661–669

    Article  Google Scholar 

  • Fava GA, Cosci F (2019) Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry 80(6):19com12794

    Article  PubMed  Google Scholar 

  • Fava M, Freeman MP, Flynn M et al (2018) Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 25(7):1592–1603

    Article  PubMed  PubMed Central  Google Scholar 

  • Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193–202

    Article  PubMed  Google Scholar 

  • Fernandes N, Prada L, Rosa MM et al (2021) The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. Clin Res Cardiol 110(2):183–193

    Article  PubMed  Google Scholar 

  • Findeis H, Ludwig V, Mikolas P et al (2022) Praktische Aspekte der Ketaminbehandlung – Sicherheit, Kombinationstherapien und Komorbiditäten [Practical aspects of ketamine treatment – Safety, combination treatment and comorbidities]. Nervenarzt 93(3):243–253

    Article  CAS  PubMed  Google Scholar 

  • Firth J, Teasdale SB, Allott K et al (2019) The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 18(3):308–324

    Article  PubMed  PubMed Central  Google Scholar 

  • FOCUS Trial Collaboration (2019) Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 393(10168):265–274

    Article  Google Scholar 

  • Fu Y, Dai Q, Zhu L, Wu S (2018) Antidepressants use and risk of cataract development: a systematic review and meta-analysis. BMC Ophthalmol 18(1):31

    Article  PubMed  PubMed Central  Google Scholar 

  • Furukawa TA, Cipriani A, Cowen PJ et al (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 6(7):601–609

    Article  PubMed  PubMed Central  Google Scholar 

  • Gastaldon C, Schoretsanitis G, Arzenton E et al (2022) Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database. Drug Saf 45(12):1539–1549

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gerhard T, Stroup TS, Correll CU et al (2020) Mortality risk of antipsychotic augmentation for adult depression. PLoS One 15(9):e239206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goodwin GM, Aaronson ST, Alvarez O et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637–1648

    Article  CAS  PubMed  Google Scholar 

  • Grabski M, McAndrew A, Lawn W et al (2022) Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry 179(2):152–162

    Article  PubMed  Google Scholar 

  • Grant JE, Chesivoir E, Valle S et al (2023) Double-blind placebo-controlled study of memantine in trichotillomania and skin-picking disorder. Am J Psychiatry 180(5):348–356

    Article  PubMed  Google Scholar 

  • Gukasyan N, Davis AK, Barrett FS et al (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol 36(2):151–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hart XM, Amann F, Brand J et al (2023) Low escitalopram concentrations in patients with depression predict treatment failure: a naturalistic retrospective study. Pharmacopsychiatry 56(2):73–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hellmann-Regen J, Clemens V, Grözinger M et al (2022) Effect of minocycline on depressive symptoms in patients with treatment-resistant depression: a randomized clinical trial. JAMA Netw Open 5(9):e2230367

    Article  PubMed  PubMed Central  Google Scholar 

  • Henssler J, Heinz A, Brandt L, Bschor T (2019) Antidepressant withdrawal and rebound phenomena. Dtsch Ärztebl Int 116(20):355–361

    PubMed  PubMed Central  Google Scholar 

  • Henssler J, Alexander D, Schwarzer G et al (2022) Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: a systematic review and meta-analysis. JAMA Psychiatry 79(4):300–312

    Article  PubMed  PubMed Central  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62

    CAS  PubMed  Google Scholar 

  • Hieronymus F, Lisinski A, Nilsson S et al (2019) Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry 6(9):745–752

    Article  PubMed  Google Scholar 

  • Horowitz MA, Taylor D (2019) Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 6(6):538–546

    Article  PubMed  Google Scholar 

  • Husain MI, Chaudhry IB, Khoso AB et al (2023) Effect of adjunctive simvastatin on depressive symptoms among adults with treatment-resistant depression: a randomized clinical trial. JAMA Netw Open 6(2):e230147

    Article  PubMed  PubMed Central  Google Scholar 

  • Jakubovski E, Varigonda AL, Freemantle N et al (2016) Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 173(2):174–183

    Article  PubMed  Google Scholar 

  • Kaster TS, Blumberger DM, Gomes T et al (2022) Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. Lancet Psychiatry 9(6):435–446

    Article  PubMed  Google Scholar 

  • Kato M, Hori H, Inoue T et al (2021) Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 26(1):118–133

    Article  CAS  PubMed  Google Scholar 

  • Kessler DS, MacNeill SJ, Tallon D (2018) Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ 363:k4218

    Article  PubMed  PubMed Central  Google Scholar 

  • Khan A, Fahl Mar K, Faucett J et al (2017) Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry 16(2):181–192

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim R, Lee TL, Lee H et al (2023) Effects of exercise on depressive symptoms in patients with Parkinson disease: a meta-analysis. Neurology 100(4):e377–e387

    Article  PubMed  Google Scholar 

  • Kishi T, Sakuma K, Hatano M et al (2023) Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Mol Psychiatry 28(3):974–976

    Article  PubMed  Google Scholar 

  • Köhler-Forsberg O, Lydholm NC, Hjorthøj C et al (2019a) Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand 139(5):404–419

    Article  PubMed  Google Scholar 

  • Köhler-Forsberg O, Gasse C, Petersen L et al (2019b) Statin treatment and the risk of depression. J Affect Disord 246:706–715

    Article  PubMed  Google Scholar 

  • Kubiszewski P, Sugita L, Kourkoulis C et al (2020) Association of selective serotonin reuptake inhibitor use after intracerebral hemorrhage with hemorrhage recurrence and depression severity. JAMA Neurol 78(1):1–8

    PubMed  PubMed Central  Google Scholar 

  • Kupfer DJ (1991) Long-term treatment of depression. J Clin Psychiatry 52(Suppl 5):28–34

    PubMed  Google Scholar 

  • Lambrichts S, Detraux J, Vansteelandt K et al (2021) Does lithium prevent relapse following successful electroconvulsive therapy for major depression? A systematic review and meta-analysis. Acta Psychiatr Scand 143(4):294–306

    Article  PubMed  Google Scholar 

  • Lenze EJ, Mulsant BH, Roose SP et al (2023) Antidepressant augmentation versus switch in treatment-resistant geriatric depression. N Engl J Med 388(12):1067–1079

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lewis G, Marston L, Duffy L et al (2021) Maintenance or discontinuation of antidepressants in primary care. N Engl J Med 385(14):1257–1267

    Article  CAS  PubMed  Google Scholar 

  • Ludwig VM, Sauer C, Young AH et al (2021) Cardiovascular effects of combining subcutaneous or intravenous esketamine and the MAO inhibitor tranylcypromine for the treatment of depression: a retrospective cohort study. Cns Drugs 35(8):881–892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Magarbeh L, Hassel C, Choi M et al (2023) ABCB1 gene variants and antidepressant treatment outcomes: a systematic review and meta-analysis including results from the CAN-BIND-1 Study. Clin Pharmacol Ther 114(1):88–117

    Article  CAS  PubMed  Google Scholar 

  • Mataix-Cols D, Fernández de la Cruz L, Monzani B, Anxiety Consortium DCS, Altemus M, Anderson P, Cukor J et al (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74(5):501–510

    Article  PubMed  Google Scholar 

  • McClintock SM, Reti IM, Carpenter LL et al (2018) Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry 79(1):16cs10905

    Article  PubMed  PubMed Central  Google Scholar 

  • McIntyre RS, Rosenblat JD, Nemeroff CB et al (2021) Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry 178(5):383–399

    Article  PubMed  PubMed Central  Google Scholar 

  • Nikayin S, Rhee TG, Cunningham ME et al (2022) Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting. JAMA Psychiatry 79(7):736–738

    Article  PubMed  PubMed Central  Google Scholar 

  • Orlova Y, Rizzoli P, Loder E (2018) Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 75(5):566–572

    Article  PubMed  PubMed Central  Google Scholar 

  • Papola D, Ostuzzi G, Tedeschi F et al (2022) Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. Br J Psychiatry 221(3):507–519

    Article  PubMed  Google Scholar 

  • Paulzen M, Haen E, Hiemke C et al (2018) Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. J Affect Disord 227:506–511

    Article  CAS  PubMed  Google Scholar 

  • Pearce M, Garcia L, Abbas A et al (2022) Association between physical activity and risk of depression: a systematic review and meta-analysis. JAMA Psychiatry 79(6):550–559

    Article  PubMed  PubMed Central  Google Scholar 

  • Philipp-Muller AE, Stephenson CJ, Moghimi E et al (2023) Combining ketamine and psychotherapy for the treatment of posttraumatic stress disorder: a systematic review and meta-analysis. J Clin Psychiatry 84(2):22br14564

    Article  PubMed  Google Scholar 

  • Phillips JL, Norris S, Talbot J et al (2020) Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology 45(4):606–612

    Article  CAS  PubMed  Google Scholar 

  • Pirkis J, John A, Shin S et al (2021) Suicide trends in the early months of the COVID-19 pandemic: an interrupted time-series analysis of preliminary data from 21 countries. Lancet Psychiatry 8(7):579–588

    Article  PubMed  PubMed Central  Google Scholar 

  • Pluijms EM, Kamperman AM, Hoogendijk WJ et al (2021) Influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy: a systematic review and meta-analysis. Aust N Z J Psychiatry 55(4):366–380

    Article  PubMed  Google Scholar 

  • Pluijms EM, Kamperman AM, Hoogendijk WJG et al (2022) Influence of adjuvant nortriptyline on the efficacy of electroconvulsive therapy: a randomized controlled trial and 1-year follow-up. Acta Psychiatr Scand 145(5):517–528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Price RB, Kissel N, Baumeister A et al (2022a) International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators. Mol Psychiatry 27(12):5096–5112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Price RB, Spotts C, Panny B et al (2022b) Novel, brief, fully automated intervention to extend the antidepressant effect of a single ketamine infusion: a randomized clinical trial. Am J Psychiatry 179(12):959–968

    Article  PubMed  Google Scholar 

  • Rae Olmsted KL, Bartoszek M, Mulvaney S et al (2020) Effect of stellate ganglion block treatment on posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Psychiatry 77(2):130–138

    Article  PubMed  Google Scholar 

  • Renoux C, Vahey S, Dell’Aniello S, Boivin JF (2017) Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol 74(2):173–180

    Article  PubMed  Google Scholar 

  • Rhee TG, Sint K, Olfson M et al (2021) Association of ECT with risks of all-cause mortality and suicide in older medicare patients. Am J Psychiatry 178(12):1089–1097

    Article  PubMed  PubMed Central  Google Scholar 

  • Rhee TG, Shim SR, Forester BP et al (2022) Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry 79(12):1162–1172

    Article  PubMed  PubMed Central  Google Scholar 

  • Rink L, Adams A, Braun C et al (2022) Dose-response relationship in selective serotonin and norepinephrine reuptake inhibitors in the treatment of major depressive disorder: a meta-analysis and network meta-analysis of randomized controlled trials. Psychother Psychosom 91(2):84–93

    Article  PubMed  Google Scholar 

  • Rutten S, Vriend C, Smit JH et al (2019) Bright light therapy for depression in Parkinson disease: a randomized controlled trial. Neurology 92(11):e1145–e1156

    Article  PubMed  Google Scholar 

  • Sachs GS, Yeung PP, Rekeda L et al (2023) Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry 180(3):241–251

    Article  PubMed  Google Scholar 

  • Scangos KW, Khambhati AN, Daly PM et al (2021) Closed-loop neuromodulation in an individual with treatment-resistant depression. Nat Med 27(10):1696–1700

    Article  CAS  PubMed  Google Scholar 

  • Schäfer I, Gast U, Hofmann A et al (2019) S3-Leitlinie Postraumatische Belastungsstörung. Springer, Berlin, Heidelberg, New York

    Book  Google Scholar 

  • Simmler LD, Li Y, Hadjas LC et al (2022) Dual action of ketamine confines addiction liability. Nature 608(7922):368–373

    Article  CAS  PubMed  Google Scholar 

  • Singh B, Kung S, Pazdernik V et al (2023) Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study. J Clin Psychiatry 84(2):22m14548

    Article  PubMed  Google Scholar 

  • Slee A, Nazareth I, Bondaronek P et al (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393(10173):768–777

    Article  CAS  PubMed  Google Scholar 

  • Stingl JC, Brockmöller J (2013) Personalisierte Pharmakotherapie. Evidenzbasierte Leitlinien und klinische Anwendung pharmakogenetischer Diagnostik. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(11):1509–1521

    Article  CAS  PubMed  Google Scholar 

  • Tabuteau H, Jones A, Anderson A et al (2022) Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry 179(7):490–499

    Article  PubMed  Google Scholar 

  • Taquet M, Sillett R, Zhu L et al (2022) Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 9(10):815–827

    Article  PubMed  PubMed Central  Google Scholar 

  • Tesfaye S, Sloan G, Petrie J et al (2022) Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet 400(10353):680–690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Undurraga J, Baldessarini RJ (2017) Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. J Psychopharmacol 31(9):1184–1189

    Article  CAS  PubMed  Google Scholar 

  • Vaccarino V, Almuwaqqat Z, Kim JH et al (2021) Association of mental stress-induced myocardial ischemia with cardiovascular events in patients with coronary heart disease. JAMA 326(18):1818–1828

    Article  PubMed  PubMed Central  Google Scholar 

  • Verdijk JPAJ, van Kessel MA, Oud M et al (2022) Pharmacological interventions to diminish cognitive side effects of electroconvulsive therapy: a systematic review and meta-analysis. Acta Psychiatr Scand 145(4):343–356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Voican CS, Corruble E, Naveau S, Perlemuter G (2014) Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 171(4):404–415

    Article  PubMed  Google Scholar 

  • Voigt JD, Leuchter AF, Carpenter LL (2021) Theta burst stimulation for the acute treatment of major depressive disorder: a systematic review and meta-analysis. Transl Psychiatry 11(1):330

    Article  PubMed  PubMed Central  Google Scholar 

  • Wallner MA, Eloge JC, Mackey IV et al (2023) Safety and tolerability of concomitant intranasal esketamine treatment with irreversible, nonselective MAOIs: a case series. J Clin Psychiatry 84(2):22cr14598

    Article  PubMed  Google Scholar 

  • Walther A, Breidenstein J, Miller R (2019) Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry 76(1):31–40

    Article  PubMed  Google Scholar 

  • Watson KT, Simard JF, Henderson VW et al (2021) Incident major depressive disorder predicted by three measures of insulin resistance: a Dutch cohort study. Am J Psychiatry 178(10):914–920

    Article  PubMed  Google Scholar 

  • Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Ärztebl Int 108(41):687–693

    PubMed  PubMed Central  Google Scholar 

  • Williams T, Phillips NJ, Stein DJ, Ipser JC (2022) Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 3(3):CD2795

    PubMed  Google Scholar 

  • Yatham MS, Yatham KS, Ravindran AV et al (2019) Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. J Affect Disord 257:55–63

    Article  CAS  PubMed  Google Scholar 

  • Zhou X, Ravindran AV, Qin B et al (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 76(4):e487–e498

    Article  PubMed  Google Scholar 

  • Zisook S, Johnson GR, Tal I et al (2019) General predictors and moderators of depression remission: a VAST-D report. Am J Psychiatry 176(5):348–357

    Article  PubMed  Google Scholar 

  • Zoellner LA, Roy-Byrne PP, Mavissakalian M et al (2019) Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD. Am J Psychiatry 176(4):287–296

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin, Deutschland

    Dr. med. Francesca Regen

  2. Mainz, Deutschland

    Prof. Dr. med. Otto Benkert

Authors
  1. Dr. med. Francesca Regen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Deutschland

    Otto Benkert

  2. ehemals Universitäts-Klinikum München, München, Deutschland

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Regen, F., Benkert, O. (2023). Antidepressiva. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-67685-1_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-67684-4

  • Online ISBN: 978-3-662-67685-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation